Diagnostic value of preoperative examination for evaluating margin status in breast cancer

doi:10.12998/wjcc.v11.i20.4852

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 20

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2669)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

WORD

HTML

1325

Figures (1-3)

353

Tables (1-2)

234

Sum=1985

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

136

Download

448

Sum=584

Jul 16, 2023 (publication date) through Nov 25, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Jul 16, 2023; 11(20): 4852-4864
Published online Jul 16, 2023. doi: 10.12998/wjcc.v11.i20.4852

Table 2 Comparison of clinical and pathological characteristics among different patients

Imaging/pathological features	Training group				Validation group
Imaging/pathological features	M+group (n = 40)	M- group (n = 186)	Statistical value	P value	M+ group (n = 17)	M- group (n = 80)	Statistical value	P value
Age	56.154 ± 13.537	59.008 ± 10.378	0.063	0.200	65.87 ± 9.31	55.98 ± 10.63	0.08	0.20
Group
BCS	19 (47.5)	185 (99.5)	χ² = 66.874	< 0.001	8 (47.1)	78 (97.5)	χ² = 29.32	< 0.001
Non-BCS	21 (52.5)	1 (0.5)	χ² = 66.874	< 0.001	9 (52.9)	2 (2.5)	χ² = 29.32	< 0.001
MRI
Lesion type
Mass	15 (37.5)	87 (46.8)	χ² = 42.153	< 0.001	8 (47.1)	54 (67.5)	χ² = 12.782	< 0.001
NME	1 (2.5)	11 (5.9)	χ² = 19.263	< 0.001	0 (0)	1 (12.5)	χ² = 1.191	0.275
Mass + NME	8 (20.0)	38 (20.4)	χ² = 14.719	< 0.001	3 (17.6)	6 (75.0)	χ² = 3.525	0.060
Mass + Mass	16 (40.0)	50 (26.9)	χ² = 8.847	0.003	6 (35.3)	14 (17.5)	χ² = 1.794	0.180
MIP_TRA
Linear	10 (25.0)	76 (40.9)	χ² = 0.816	0.366	1 (5.9)	26 (32.5)	χ² = 1.575	0.209
Multiple punctate	18 (45.0)	4 (2.2)	χ² = 34.67	< 0.001	8 (47.0)	4 (5.0)	χ² = 1.166	0.280
Symmetric	5 (12.5)	27 (14.5)	χ² = 0.687	0.407	3 (5.9)	8 (10.0)	χ² < 0.001	1.000
None	7 (17.5)	79 (42.5)	χ² = 2.986	0.084	5 (29.4)	42 (52.5)	χ² < 0.001	1.000
Enhancement
Heterogeneous	29 (72.5)	146 (78.5)	χ² = 0.039	0.843	16 (86.7)	59 (73.8)	χ² = 0.554	0.457
Homogeneous	8 (20.0)	29 (15.6)	χ² = 0.075	0.784	1 (6.7)	17 (21.3)	χ² = 0.760	0.383
Rim enhancement	3 (7.5)	11 (5.9)	χ² = 0.005	0.942	0 (6.7)	4 (5.0)	χ² < 0.001	1.000
Tumor size	2.5 (1.1, 6.0)	2.08 (0.50, 5.40)	0.099	0.001	2.27 (1.3, 5.0)	1.95 (0.80, 6.70)	χ² = 0.751	< 0.001
Time_Intensity_Curve
Type I	3 (7.5)	29 (15.6)	χ² = 1.619	0.203	2 (11.8)	20 (25.0)	χ² < 0.001	1.000
Type II	7 (17.5)	61 (32.8)	χ² = 0.078	0.780	8 (47.1)	25 (31.3)	χ² = 0.133	0.715
Type III	30 (75.0)	96 (51.6)	χ² = 20.197	< 0.001	7 (41.2)	35 (43.8)	χ² = 0.512	0.474
Margin
Clear	3 (7.5)	21 (11.29)	χ² < 0.001	1.000	2 (11.8)	10 (12.5)	χ² = 0.025	0.875
Unclear	8 (20.0)	28 (15.05)	χ² = 0.028	0.868	5 (29.4)	16 (20.0)	χ² = 0.088	0.767
Spiculated	29 (72.5)	137 (73.66)	χ² = 0.089	0.766	10 (58.8)	54 (67.5)	χ² < 0.001	1.000
Shape
Irregular	30 (75)	111 (59.7)	χ² = 0.294	0.588	14 (82.4)	53 (66.3)	χ² = 7.335	0.007
Roundish	5 (12.5)	59 (31.7)	χ² = 0.545	0.460	3 (17.6)	19 (23.8)	χ² = 5.058	0.025
Multiple nodules	5 (12.5)	16 (8.6)	χ² < 0.001	1.000	0 (0.0)	8 (10.0)	χ² = 0.301	0.583
MT
Tumor shape
High_Density_Nodule	1 (2.5)	9 (4.8)	χ² < 0.001	1.000	0 (0.0)	8 (10.0)	χ² < 0.001	1.000
Regular mass	21 (52.5)	113 (60.8)	χ² = 3.436	0.064	13 (76.5)	46 (57.5)	χ² = 9.529	0.002
Irregular mass	3 (7.5)	35 (18.8)	χ² = 0.056	0.813	4 (23.5)	13 (16.3)	χ² = 11.054	0.001
Undetected	15 (37.5)	29 (15.6)	χ² = 5.565	0.018	2 (11.8)	13 (16.3)	χ² = 235	0.628
Margin
Clear	6 (15.0)	24 (12.9)	χ² = 1.108	0.292	3 (17.6)	13 (16.3)	χ² = 0.590	0.442
Unclear	10 (25.0)	83 (44.6)	χ² < 0.001	0.993	7 (41.2)	37 (46.3)	χ² < 0.001	1.000
Spiculated	9 (22.5)	62 (33.3)	χ² = 0.436	0.509	5 (29.4)	24 (30.0)	χ² < 0.001	1.000
Undetected	15 (37.5)	17 (9.14)	χ² = 5.565	0.018	2 (11.8)	6 (7.50)	χ² = 0.235	0.628
US
Margin
Clear	18 (45.0)	55 (29.6)	χ² = 0.604	0.437	3 (17.6)	19 (23.8)	χ² = 0.117	0.733
Unclear	10 (25.0)	72 (38.7)	χ² = 1.084	0.298	9 (52.9)	40 (50.0)	χ² = 0.001	0.977
Spiculated	9 (22.5)	59 (31.7)	χ² = 0.096	0.756	5 (29.4)	21 (26.3)	χ² = 0.009	0.926
Multifocality
Multifocality	10 (25.0)	29 (9.0)	χ² = 0.383	0.536	4 (23.5)	10 (12.5)	χ² < 0.001	1.000
Univocality	30 (75.0)	157 (91.0)	χ² = 0.383	0.536	13 (76.5)	70 (87.5)	χ² < 0.001	1.000
ER
Positive	31 (77.5)	163 (87.6)	χ² = 4.866	0.027	15 (88.2)	71 (88.8)	χ² = 0.301	0.583
Negative	9 (22.5)	23 (12.4)	χ² = 4.866	0.027	2 (11.8)	9 (11.3)	χ² = 0.301	0.583
PR
Positive	30 (73.1)	145 (78.0)	χ² = 0.864	0.353	14 (82.4)	67 (83.8)	χ² = 0.295	0.587
Negative	10 (26.9)	41 (22.0)	χ² = 0.864	0.353	3 (17.6)	13 (16.3)	χ² = 0.295	0.587
Molecular subtypes
Luminal A	9 (22.5)	64 (34.4)	χ² = 0.545	0.460	1 (6.7)	31 (38.8)	χ² = 0.643	0.423
LuminalB_Her2(-)	16 (40.0)	70 (37.6)	χ² = 0.152	0.696	8 (47.1)	33 (41.3)	χ² = 2.363	0.124
LuminalB_Her2(+)	5 (12.5)	29 (15.6)	χ² = 0.410	0.522	5 (29.4)	9 (11.3)	χ² < 0.001	1.000
HER2_enriched	6 (15.0)	6 (3.2)	χ² = 9.549	0.002	2 (11.8)	4 (5.0)	χ² < 0.001	1.000
TNBC	4 (10.0)	17 (9.1)	χ² = 0.008	0.928	0 (0.0)	3 (3.8)	χ² = 0.089	0.766

BCS: Breast-conserving surgery; MIP: Maximal intensity projection; NME: Non-mass enhancement; MRI: Magnetic resonance imaging; US: Ultrasound; MT: Molybdenum target examination; ER: Estrogen receptor; PR: Progesterone receptor.

Citation: Liu P, Zhao Y, Rong DD, Li KF, Wang YJ, Zhao J, Kang H. Diagnostic value of preoperative examination for evaluating margin status in breast cancer. World J Clin Cases 2023; 11(20): 4852-4864
URL: https://www.wjgnet.com/2307-8960/full/v11/i20/4852.htm
DOI: https://dx.doi.org/10.12998/wjcc.v11.i20.4852